Teligent, Inc. TLGTQ OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

25/100

1/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Teligent, Inc. (TLGTQ) generated $-6.54M in operating cash flow for quarter ending 2021-06-30. After capital expenditures of $182K, free cash flow was $-6.72M.

Free cash flow margin was -64.4% of revenue. Cash conversion ratio was 0.51x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
MOAT (0/100, Fail) — limited free cash flow weakens the competitive position
INCOME (10/100) — Cash conversion ratio was 0.51x suggests some earnings are non-cash items

Overall SharesGrow Score: 24/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

25/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

0/100

Proven by this page

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Teligent, Inc. Cash Flow History

Metric	TTM	Q2 FY2021	Q1 FY2021	Q4 FY2020	Q3 FY2020
Operating Cash Flow	$-23.04M	$-6.54M	$-10.87M	$-1.16M	$-4.46M
Capital Expenditure	$-1.89M	$-182K	$-47K	$-870K	$-795K
Free Cash Flow	$-24.93M	$-6.72M	$-10.92M	$-2.03M	$-5.26M